Search
News & Events
Study finds folate protects against childhood brain tumoursA national study led by Perth's Telethon Institute has found that folic acid supplements before and during pregnancy reduces the risk of childhood brain tumours
News & Events
New insight into treatment options for rare childhood brain tumour, 2011 Media Release, Telethon Institute for Child Health ResearchA new study led by Australian researchers has outlined for the first time the best treatment options for children suffering from meningioma
News & Events
Continuing the cancer fightWork by the Institute's Division of Children's Leukaemia and Cancer Research has been recognised with three research grants from the Cancer Council of WA.
News & Events
Apache Energy joins Telethon Institute in cancer research partnershipApache Energy and the Telethon Institute for Child Health Research today signed a two-year partnership
News & Events
New study examines vacccine to prevent cervical cancerThe Telethon Institute for Child Health Research today announced a new study investigating a vaccine to prevent infection of Human Papilloma Virus (HPV).
Research
Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemiaPre-clinical models that effectively recapitulate human disease are critical for expanding our knowledge of cancer biology and drug resistance mechanisms.
Research
National Case-Control Study of Childhood Brain TumoursThe Australian Study of Childhood Brain Tumours was a national case-control study into the risk factors for childhood brain tumours (CBT).
News & Events
Setting the agenda: Urgent priorities to close the childhood cancer gap for Aboriginal and Torres Strait Islander childrenA review led by the First Nations Childhood Cancer team at The Kids Research Institute Australia has highlighted the urgent need for Indigenous-specific studies focused on cancer outcomes, survivorship and equity.
Research
PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumoursOur findings define PTPN2 as a target for bolstering T-cell-mediated anti-tumour immunity and CAR T-cell therapy against solid tumours.